1) Advocacy to reform IPAB to ensure patient access to medically necessary therapies. 
2) Implementation of biosimilars regulations to support incentives for innovation and second generation therapies. Support corporate tax policies which protect US research and manufacturing jobs, including issues related to transfer pricing and R&D credit. Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.  Opposition to inclusion of patent settlements legislation in appropriations bill.
HCR - Health Issues TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid CPT - Copyright/Patent/Trademark
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
BIOGEN
601 PENNSYLVANIA AVENUE, NW #720, WASHINGTON, DC, 20004, US
KATHLEEN TREGONING (Staff, House Ways and Means Committee) ADAM GLUCK (Staff, Senate HELP Committe) KATHLEEN TREGONING (Staff, House Ways and Means Committee) ADAM GLUCK (Staff, Senate HELP Committee) KATHLEEN TREGONING (Staff, House Ways and Means Committee) ADAM GLUCK (Staff, Senate HELP Committee) KATHLEEN TREGONING (Staff, House Ways and Means Committee) ADAM GLUCK (Staff, Senate HELP Committee)
Staff, House Ways and Means Committee Staff, Senate HELP Committe Staff, House Ways and Means Committee Staff, Senate HELP Committee Staff, House Ways and Means Committee Staff, Senate HELP Committee Staff, House Ways and Means Committee Staff, Senate HELP Committee